Skip to content
2000
Volume 15, Issue 3
  • ISSN: 1570-1794
  • E-ISSN: 1875-6271

Abstract

Background: Indolizine pharmacophore is known to exhibit various promising pharmacological properties such as analgesic, anticancer, antihistaminic, antidiabetic, anti-inflammatory, antileishmanic, antimicrobial, antimutagenic, antioxidant, antitubercular, antiviral, larvicidal and herbicidal activities. Objective: In the present investigation, it was envisaged to synthesize a series of novel ethyl-7-substituted-3-(4- substituted benzoyl)-2-substituted indolizine-1-carboxylates by employing chromium(IV)oxide as dehydrogenating agent with triethylamine combination. Method: Synthesis of a series of proposed polysubstituted indolizines by employing chromium(IV)oxide as dehydrogenating agent with triethylamine combination. Final compounds were characterized by spectroscopic techniques viz fourier-transform infrared spectroscopy, nuclear magnetic resonance spectroscopy, liquid chromatography- mass spectrometry, elemental analysis and selected title compound diethyl-3-(4- cyanobenzoyl)indolizine-1,2-dicarboxylate by single crystal X-ray method. Results: Aromatic cycloimmoniumylides undergo smooth cyclization with electron-deficient alkenes in the presence of triethylamine and DMF at room temperature to afford intermediates ethyl 7-substituted-2- substituted-3-(4-substituted benzoyl)-1,2,3,8a-tetrahydroindolizine-1-carboxylates, which on dehydrogenation with chromium(IV)oxide to obtain the title compounds ethyl-7-substituted-3-(4-substituted benzoyl)-2- substituted indolizine-1-carboxylates. Conclusion: The research was focused on developing an efficient protocol for the synthesis of a novel series of ethyl 3-substituted benzoyl-7-substituted-2-substituted indolizine-1-carboxylates with suitable pharmacological properties in good to excellent yields.

Loading

Article metrics loading...

/content/journals/cos/10.2174/1570179414666171024155051
2018-05-01
2024-12-24
Loading full text...

Full text loading...

/content/journals/cos/10.2174/1570179414666171024155051
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test